Price T Rowe Associates Inc Intercept Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $44,185 - $82,754	4,423 Added 20.14%	26,386 $490,000
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $3,521 - $7,407	384 Added 1.78%	21,963 $243,000
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $1,791 - $3,104	143 Added 0.67%	21,579 $290,000
Q4 2022 Feb 14, 2023	BUY	$11.61 - $16.11 $5,410 - $7,507	466 Added 2.22%	21,436 $265,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $17,655 - $28,486	1,446 Added 7.41%	20,970 $293,000
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $15,351 - $26,779	-1,367 Reduced 6.54%	19,524 $270,000
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $87,212 - $116,044	-6,523 Reduced 23.79%	20,891 $340,000
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $391,471 - $535,395	27,414 New	27,414 $447,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.